Nuvectis Pharma, Inc. (NVCT) Stock Score, Valuation & Financial Research

Nuvectis Pharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NVCT

Nuvectis Pharma, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 19.95. These figures are a research snapshot, not a buy or sell recommendation.

What Nuvectis Pharma, Inc. does

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Nuvectis Pharma is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of precision medicine product candidates for oncology, relying on capital raises to fund clinical trials and operational expenses.

Products and services

  • The company is developing NXP900, a small molecule SRC/YES1 kinase inhibitor, and NXP800, an oral small molecule inhibitor of the HSF1 pathway.

Customer types

Oncology patients with unmet medical needs.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its drug candidates. Source

Business strengths to evaluate

  • Focus on precision medicine for oncology Source

Business risks and research considerations

  • History of operating losses and need for additional capital Source
  • Dependence on third-party manufacturers and clinical trial sites Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NVCT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 19.95
Market capitalization:
529.4M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -27.85M
Free cash flow:
USD -16.01M
Cash:
USD 22.16M
Total debt:
USD 0.00
EPS:
USD -1.31

What stands out

  • Free cash flow is USD -16.01M, negative for the stored period.
  • The balance sheet shows USD 22.16M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 22.16M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NVCT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NVCT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NVCT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NVCT to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of NVCT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research NVCT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.